Regulatory T-cell differentiation and associated immune pathways (Treg differentiation)

Regulatory T-cell (Treg) differentiation is a fundamental immunological process required for maintaining self-tolerance and immune homeostasis (Sakaguchi et al., 2008, Nature). This differentiation is primarily characterized by the expression of the master transcription factor FOXP3, which orchestrates the suppressive program of these cells (Fontenot et al., 2003, Nature Immunology). The associated immune pathways involve critical signaling nodes including the IL-2/STAT5 axis, TGF-beta signaling, and T-cell receptor (TCR) engagement (Josefowicz et al., 2012, Annual Review of Immunology). In clinical settings, defects in these pathways lead to severe multi-organ autoimmunity, such as IPEX syndrome, whereas the accumulation of Tregs in tumors contributes to immune evasion (Plitas & Rudensky, 2016, Immunity). Therapeutic modulation of these pathways includes the use of low-dose IL-2 to selectively expand Treg populations in autoimmune diseases (Klatzmann & Abbas, 2015, Nature Reviews Immunology). Conversely, mTOR inhibitors like sirolimus are used to favor Treg lineage stability and survival over effector T cells in transplant settings. Emerging therapies also explore the depletion of Tregs or the inhibition of their suppressive function to enhance anti-tumor immunity in cancer patients. Overall, these pathways represent a delicate balance between preventing autoimmunity and allowing effective responses against pathogens and tumors.

Other names

Treg developmentFOXP3-mediated differentiationRegulatory T-cell maturationTreg signaling pathways

Modulation of the IL-2/STAT5 signaling axis, inhibition of mTOR to favor Treg expansion, and induction of FOXP3 expression to promote suppressive phenotypes.